Top Markets
Coin of the day
IntelGenx Technologies Corp. IntelGenx Technologies Corp.

IntelGenx Technologies Corp.

IGX
株式のランク #28342
IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise... IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.
株価
$0.17446996
最終同期: 2024-06-11
時価総額
$26.97M
変化(1日)
-0.57%
変化(1年)
0.00%
CA
取引 IntelGenx Technologies Corp. (IGX)

カテゴリー

IntelGenx Technologies Corp.(IGX)のP/S比率
2026 時点のP/S比率 TTM: 0
IntelGenx Technologies Corp. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
IntelGenx Technologies Corp. の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH